VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
← Pulse/Companies

Apnimed on Pulse

Biotech

The full thread of our Apnimed coverage — a running record of every development we've tracked, with the VC take on each.

3
Stories
2
With a headline figure
Jul 10, 2026
Since

Coverage Timeline

newest first
  1. Jul 27, 2026IPOApnimed Launches $150M IPO for Sleep Apnea Pill$150M-$160M IPO→
  2. Jul 27, 2026IPOApnimed Launches $150M IPO For First Sleep Apnea Pillup to $150M IPO→
  3. Jul 10, 2026IPOApnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill→

All Coverage

IPO· Jul 27, 2026

Apnimed Launches $150M IPO for Sleep Apnea Pill

Illustration for: Apnimed Launches $150M IPO for Sleep Apnea Pill
IPO$150M-$160M IPO

Apnimed Launches $150M IPO for Sleep Apnea Pill

Apnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.

Jul 27, 2026
IPO· Jul 27, 2026

Apnimed Launches $150M IPO For First Sleep Apnea Pill

Illustration for: Apnimed Launches $150M IPO For First Sleep Apnea Pill
IPOup to $150M IPO

Apnimed Launches $150M IPO For First Sleep Apnea Pill

Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.

Jul 27, 2026
IPO· Jul 10, 2026

Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill

Illustration for: Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO

Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill

Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.

Jul 10, 2026
@Trace_Cohen·t@nyvp.com